PHARMA

May 15 2020

Management Team, FutuRx, pharma projects.

#Pharma #projects



Management Team

Pharma projects

Einat Zisman, PhD, MBA

Dr. Einat Zisman is the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator that was established in January 2014 by OrbiMed Israel Partners, Johnson Johnson Innovation, JJDC and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. after winning the tender of the Office of the Chief Scientist (OCS) in Israel.

Prior to joining FutuRx, Dr. Zisman served as the CEO of Hadasit Medical Research Services Development Ltd., the Technology Transfer Organization (TTO) and commercial arm of Hadassah Medical Organization in Jerusalem, Israel. Before joining Hadasit, Dr. Zisman served as the Chief Business Officer of Yeda, the technology transfer arm of the Weizmann Institute of Science.

Dr. Zisman holds an MBA from the Marshall Business School, University of Southern California, USA, a PhD from the Weizmann Institute of Science and a B.Pharm degree from the Hebrew University of Jerusalem. Dr. Zisman s expertise is in building value via licensing, partnering, financing and marketing of early stage technologies.

Pharma projects

Leah N Klapper, PhD

Leah Klapper has been leading research and development in biotech start-ups for close to 20 years focusing on the advancement of academic programs from discovery to clinical proof of concept. Before joining FutuRx as CTO Leah served as CSO of Regenovation Ltd., a company developing acellular novel materials for in-situ tissue regeneration.

Prior to joining Regenovation Leah served as CSO of BioLineRx Ltd., a leading public drug development company, as General Manager of Bioline Innovations Jerusalem; an innovative biotechnology incubator and as Vice President of Research and Development at CureTech Ltd., a company developing novel immune-modulating molecules.

Leah gained her post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle Washington in the fields of translational medicine and immune-therapeutics, and holds a PhD in Immunology and Molecular Biology from the Weizmann Institute of Science in Rehovot Israel.

Pharma projects

Galit Yosha, LLB, MBA

Mrs. Yosha has over 15 years of experience in various aspects of commercial, civil and IP law. Prior to joining FutuRx, Mrs. Yosha served as a legal counsel at Yeda Research and Development Ltd., the Technology Transfer Organization (TTO) and commercial arm of the Weizmann Institute of Science. Before joining Yeda, Mrs. Yosha practiced IP and commerce litigation at several leading Israeli law firms.

In 2012, Mrs. Yosha was elected to serve as a mediator under the Israeli Courts Administration ADR program, and obtained vast experience in resolving varied legal disputes by way of mediation.

Mrs. Yosha holds an MBA from the Israeli College of Management, and an LLB from the Hebrew University of Jerusalem.

Her expertise are in the areas of licensing and technology transfer.

Pharma projects

Shmuel Tuvia, Ph.D

Dr. Tuvia s experience with drug development began in 1990s. Prior to joining FutuRx, Dr. Tuvia established and served as COO at Eloxx Pharmaceuticals, a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations.

Prior to Eloxx, Dr. Tuvia served as VP of Preclinical research at Chiasma Pharmaceuticals Ltd.

Previously, he worked in several biotech companies where he focused on discovery and development of new drugs and technologies.

Dr. Tuvia conducted postdoctoral research at Duke University Medical Center, in Durham North Carolina. He earned his PhD with Distinction at the Sackler School of Medicine, Tel-Aviv University, Israel and hold MSc. and BSc. degrees in biology from the Tel-Aviv University, Israel. Dr. Tuvia has published approximately 20 peer-reviewed scientific articles and is the inventor of a number of patents.

Pharma projects

Moshe Talbi, CPA, MBA

Prior to joining FutuRx, Mr. Talbi served as Head of Financial Reporting and Business Development Director of Gefen Biomed Ltd., (TASE: GEFEN-S) a publicly traded accelerator, specializing in early stage medical devices and pharma projects.

Before joining Gefen Biomed, he served as Head of Sourcing and Financial Controller in Novartis Pharma Israeli branch. Mr. Talbi holds an MBA from the Recanati Business School, University of Tel Aviv, Israel, he is a Certified Public Accountant (IL) and holds a B.A in economics, Tel Aviv University.

His expertise are in the areas of operational optimization, strategic planning, budgeting, tax accounting, financial analysis, controls, M A, and public financing.

Pharma projects

Limor Miara, MSc, DVM

Dr. Limor Miara (D.V.M) has over 9 years of experience in animal toxicology and preclinical management: in vivo, in vitro and cell free.

At Chiasma Dr. Miara led a preclinical team as part of product development in several programs focused on autoimmune diseases, chronic inflammation and endocrinology. Previously, as head of Pharmacology and Toxicology at D-Pharm, Ltd., she led a preclinical research and development team focused on ischemic stroke, hemorrhagic stroke, epilepsy and other CNS models.

Her expertise are in preclinical drug development. Dr. Miara holds B.Sc. (with high honors), M.Sc. and D.V.M. degrees from the Hebrew University. She is also one of few people, in the world, to have performed brain surgery on a lion.

Pharma projects

Sigal Arad

Sigal handles the Human Resource (HR) and Administration operation at FutuRx and its portfolio companies. She is leading the HR strategy of the group, including establishing and applying policies, managing the recruitment training process, handling the interface between FutuRx management and portfolio companies, and providing solutions to improve employees’ satisfaction.

Prior to joining FutuRx in 2014, Sigal worked for 9 years at YEDA the commercial arm of The Weizmann Institute of Science and over 6 years at several Embassies of Israel around the world.



Written by admin


Leave a Reply